drugset / Trial / NCT05532722
ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Non-randomizedSequentialOpen-labelTreatment
Summary
An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)
Timeline
- Start
- 2022-09-28
- Primary completion
- 2025-08-28
- Completion
- 2026-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulviprubart | Monoclonal antibody | 0.25 mg/kg | Subcutaneous |
| Subject | Ulviprubart | Monoclonal antibody | 0.75 mg/kg | Subcutaneous |
| Subject | Ulviprubart | Monoclonal antibody | 1.5 mg/kg | Subcutaneous |
| Subject | Ulviprubart | Monoclonal antibody | 3 mg/kg | Subcutaneous |